Endocrine/women's health companies
23 listed endocrine/women's health companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Corcept Therapeutics Inc | CORT | Korlym (mifepristone) | hypercortisolism / Cushing's syndrome | — |
| Rhythm Pharmaceuticals, Inc. | RYTM | IMCIVREE (setmelanotide) | obesity/hyperphagia due to POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity | 2026 — initiate pivotal Phase 3 trial in acquired HO |
| AbCellera Biologics Inc. | ABCL | ABCL635 | Moderate-to-severe vasomotor symptoms (VMS) associated with menopause | Q4 2026 — Phase 1 topline data readout |
| Organon & Co. | OGN | Nexplanon (etonogestrel implant) | contraception | H2 2026 — US commercial launch |
| Amylyx Pharmaceuticals, Inc. | AMLX | avexitide | post-bariatric hypoglycemia (PBH) | 2027 — IND submission |
| MBX Biosciences, Inc. | MBX | canvuparatide (MBX 2109) | Chronic hypoparathyroidism | Q4 2026 — Results from first cohort of 12-week MAD portion of Phase 1 |
| Xeris Biopharma Holdings, Inc. | XERS | Recorlev, Gvoke, Keveyis (commercial portfolio) | Cushing's syndrome (endogenous hypercortisolemia); severe hypoglycemia; primary periodic paralysis | 2026 — Initiate Phase 3 clinical trial |
| Eton Pharmaceuticals, Inc. | ETON | INCRELEX (mecasermin) | severe primary IGF-1 deficiency | March 29, 2027 — Type 9 NDA for LIBERVANT ages 6-11 expansion has PDUFA target action date of March 29, 2027. |
| Tandem Diabetes Care Inc | TNDM | t:slim X2 / Tandem Mobi with Control-IQ+ (insulin pumps, AID) | insulin-dependent diabetes (type 1 and type 2) | — |
| Beta Bionics, Inc. | BBNX | iLet Bionic Pancreas | type 1 diabetes (insulin delivery) | Q2 2027 — 510(k) clearance and full commercialization |
| Sana Biotechnology, Inc. | SANA | SC451 | type 1 diabetes | 2026 — IND filing and begin Phase 1/2 clinical trial |
| Entera Bio Ltd. | ENTX | EB613 (oral PTH(1-34) tablet) | Postmenopausal osteoporosis | H2 2026 — Initiation of Phase 3 registrational program (single ~750-patient placebo-controlled trial) |
| Rezolute, Inc. | RZLT | Ersodetug (RZ358) | Hypoglycemia due to tumor hyperinsulinism (upLIFT); congenital hyperinsulinism (sunRIZE) | — |
| Vogenx, Inc. | VOGX | mizagliflozin | Post-bariatric hypoglycemia (PBH) | 2026 — Begin patient screening in Phase 2b EMERGE study |
| Utah Medical Products Inc | UTMD | Medical device portfolio (Filshie Clip System, Deltran pressure transducers, neonatal and obstetric devices) | — | 2027 — Litigation cases in two courts will apparently go to trial in 2027. |
| Yarrow Bioscience, Inc. | YARW | YB-101 (GenSci098) | Graves' disease; thyroid eye disease planned | Q4 2026 — Final report of repeat non-clinical toxicology study in male dogs |
| Oramed Pharmaceuticals Inc. | ORMP | None (strategic investment holding; legacy oral insulin ORMD-0801) | Not applicable | — |
| Dare Bioscience, Inc. | DARE | Ovaprene | hormone-free monthly intravaginal contraception | 2027 — Top-line data from pivotal Phase 3 study |
| Femasys Inc | FEMY | FemBloc permanent birth control system | non-surgical permanent female contraception | — |
| Pulsenmore Ltd. | PLSM | Pulsenmore ES | home prenatal ultrasound | — |
| Palatin Technologies, Inc. | PTN | MC4R selective long-acting peptide agonist | Rare obesity disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome) | — |
| Trinity Biotech PLC | TRIB | Continuous glucose monitor (CGM) biosensor | diabetes management | — |
| INVO Fertility, Inc. | IVF | INVOcell device / fertility clinic network | assisted reproductive technology (IVF and intravaginal culture) | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.